We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic ...

Rimegepant (also called Vydura and made by Pfizer) is recommended as an option for preventing episodic migraine in adults ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

1.1 Ibrutinib plus venetoclax is recommended, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. This is only if the companies provide both ...

There are simple discount patient access schemes for ibrutinib and venetoclax. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

4.1 Further comparative clinical-effectiveness evidence on the CamPROBE biopsy device is recommended to understand how double freehand prostate biopsy approaches compare with transrectal ultrasound ...

Review and download supporting evidence. Includes the full guideline if available.

NICE intends to develop tools, in association with relevant stakeholders, to help organisations put this guidance into practice. In addition, NICE will support this guidance through a range of ...